ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
BeOne Medicines Ltd.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$370.17+1.11 (+0.30%)
Close on Oct 19, 2026
- Market cap
- $557.24B
- P/E (TTM)
- 860.9
- Dividend yield
- –
Share price
+$53.75 (+16.99%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
BeOne Medicines Ltd. grew revenue 34.3% to $6.13B over the twelve months to Jun 30, 2026. Free cash flow was $1.33B, up 443.3% from a year earlier.
Revenue
$6.13B
+34.3% vs. a year earlier
Operating income
$923.10M
TTM Q2 2026
Free cash flow
$1.33B
+443.3% vs. a year earlier
EPS, diluted
$0.43
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $557.24B
- P/E ratio
- 860.9
- Price to sales
- 90.92
- Price to book
- 107.70
- Dividend yield
- –
- Free cash flow yield
- 0.24%
Fundamentals
- Revenue
- $6.13B
- Net income
- $655.71M
- EPS, diluted
- $0.43
- Free cash flow
- $1.33B
- Book value per share
- $3.44
- Diluted shares
- 1.51B
Thirteen years at a glance
Fiscal years 2013 to 2025 and trailing twelve months, USD
Revenue
$6.13B+34.3% YoY
Gross profit
$5.45B+39.7% YoY
Operating income
$923.10M
Net income
$655.71M
EPS, diluted
$0.43
Free cash flow
$1.33B+443.3% YoY
Reported periodTrailing twelve months